Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium
Journal of Labelled Compounds and Radiopharmaceuticals · 2025
DOI: 10.1002/jlcr.4168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Bachir Latli und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Deuterium, Erb-b2 Receptor Tyrosine Kinases, Carbon Radioisotopes, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
BI 1584142 (1) and BI 1810631 (2, zongertinib) are potent and selective HER2 tyrosine kinase inhibitors being developed for the treatment of non–small cell lung cancer. Carbon‐14–labeled versions of these drug candidates were needed to study their absorption, distribution, metabolism, and excretion in animals and in humans. BI 1584142 and BI 1810631 differ in two moieties; the former contains a piperazine and the latter a 4‐aminopiperidine. Therefore, a common carbon‐14–labeled intermediate like the sulfoxide [ 14 C]‐8 was prepared in four radioactive steps and used to provide [ 14 C]‐1 and [ 14 C]‐2 in two and three extra steps, respectively. Deuterium‐labeled 1 and 2 were also synthesized as internal standards, using piperazine‐ d 8 and 4‐aminopiperidine‐ d 9 for bioanalytical studies and other studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
ORCID-Profile: Bachir Latli
Zitieren
APA
Latli, B., & Chong, E. (2025). Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4168
Vancouver
Latli B, Chong E. Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4168
BibTeX
@article{Latli2025,
author = {Latli, Bachir and Chong, Eugene},
title = {Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2025},
doi = {10.1002/jlcr.4168}
}
EUVIMED